# Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

> **NCT01366521** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 70 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Mepolizumab

## Key facts

- **NCT ID:** NCT01366521
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01366521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01366521, "Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01366521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*